Steven Cohen Glycomimetics Inc Transaction History

Point72 Asset Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$8.47 - $14.71 $1.57 Million - $2.72 Million	-185,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$13.7 - $17.12 $68,500 - $85,600	5,000 Added 2.78%	185,000 $2.66 Million
Q2 2018 Aug 14, 2018	BUY	$14.63 - $19.19 $774,877 - $1.02 Million	52,965 Added 41.69%	180,000 $2.9 Million
Q1 2018 May 15, 2018	BUY	$16.06 - $25.35 $2.04 Million - $3.22 Million	127,035 New	127,035 $2.06 Million

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.